Novel bacterial topoisomerase inhibitors derived from isomannide - Sophion

Novel bacterial topoisomerase inhibitors derived from isomannide


Author(s): Antony Okumu, Yanran Lu, Sheri Dellos-Nolan, Jonathan L. Papa, Bryan Koci, Nicholas T. Cockroft, Judith Gallucci, Daniel J. Wozniak, Jack C. Yalowich, Mark J. Mitton-Fry


A series of Novel Bacterial Topoisomerase Inhibitors (NBTIs) employing a linker derived from isomannide were synthesized and evaluated. Reduced hERG inhibition was observed compared to structure-matched analogues with different linkers, and compound 6 showed minimal proarrhythmic potential using an in vitro panel of cardiac ion channels. Compound 6 also displayed excellent activity against fluoroquinolone-resistant MRSA (MIC90 = 2 μg/mL) and other Gram-positive pathogens.

Contact

Contact Sophion

Sophion Bioscience A/S
Baltorpvej 154, 2750 Ballerup, Denmark
Telephone: +45 44 60 88 00

You need to fill in all required fields.

When opting-in for our newsletter you will receive 4-6 newsletters per year. You can always opt-out directly from the newsletters. For more information see our privacy policy